EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

NPM 1 Mutations in AML—The Landscape in 2023

Naman Sharma, Jane L Liesveld

Cancers · 12.02.2023 · 15 (4) · 1177

DOI: 10.3390/cancers15041177 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 12.02.2023. Verfasst von Naman Sharma und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, University of Massachusetts-Baystate Medical Center, Springfield, MA 01199, USA. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) represents 80% of acute leukemia in adults and is characterized by clonal expansion of hematopoietic stem cells secondary to genomic mutations, rendering a selective growth advantage to the mutant clones. NPM1mut is found in around 30% of AML and clinically presents with leukocytosis, high blast percentage and extramedullary involvement. Considered as a “gate-keeper” mutation, NPM1mut appears to be a “first hit” in the process of leukemogenesis and development of overt leukemia. Commonly associated with other mutations (e.g., FLT 3, DNMT3A, TET2, SF3B1), NPM1 mutation in AML has an important role in diagnosis, prognosis, treatment and post-treatment monitoring. Several novel therapies targeting NPM1 are being developed in various clinical phases with demonstration of efficacy. In this review, we summarize the pathophysiology of the NPM1 gene mutation in AML, clinical implications and the novel targeted therapies to date.

Schlagwörter

Stichwörter der Autor:innen

CAR-T cellsXPO1 inhibitorsacute myeloid leukemia (AML)arsenic trioxideexportin 1menin inhibitorsminimal residual disease (MRD)nucleophosmin (NPM1) mutation

Autor:innen und Institutionen

  • Department of Hematology and Oncology, University of Massachusetts-Baystate Medical Center, Springfield, MA 01199, USA.
  • Department of Medicine, Hematology/Oncology, James P. Wilmot Cancer Institute, University of Rochester, Rochester, NY 14642, USA.

Zitieren

APA

Sharma, N., & Liesveld, J. L. (2023). NPM 1 Mutations in AML—The Landscape in 2023. Cancers, 15(4), 1177. https://doi.org/10.3390/cancers15041177

Vancouver

Sharma N, Liesveld JL. NPM 1 Mutations in AML—The Landscape in 2023. Cancers. 2023;15(4):1177. doi:10.3390/cancers15041177

BibTeX
@article{Sharma2023,
  author = {Sharma, Naman and Liesveld, Jane L},
  title = {NPM 1 Mutations in AML—The Landscape in 2023},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {4},
  pages = {1177},
  doi = {10.3390/cancers15041177}
}
Kostenlos starten →